Ross Enterprise Resources

FDA Seeks Clarity on Complementary & Alternative Products: Misinterpretation of DRAFT GUIDANCE Causes Unwarranted Concerns; DSHEA is Safe

Article


Description:

Earlier this year, the Food and Drug Administration (FDA) released a Draft Guidance for Industry on Complementary and Alternative Medicine (CAM) Products and Their Regulation by FDA. As a result of a few typographical errors and some confusion over the comment deadline, FDA extended the comment period to May 29, 2007. In addition, there has been some misinformation and confusion about the purpose and effect of this Draft Guidance. While CRN has expressed concerns about specific items in the Draft Guidance, it is important to understand what this document is and how it would be used by the agency.



Please complete the registration form below for this article.
If the information below is not yours, please click here.
* Required
 

*First Name:   *Last Name:  
Job Title:   *Email:  
*Company:   *Phone:  
Address1:   Address2:  
*City:   *State:  
*Postal Code:   *Country:  
Industry: